Study S001521

A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD STUDY IN HEALTHY ADULT MALE PARTICIPANTS TO ASSESS THE MASS BALANCE, ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND PHARMACOKINETICS OF [14C]PF-06882961

ClinicalTrials.gov record

Registration

Registration: NCT04495140
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 6
Start: 2020-07-22
Primary completion: 2020-10-15
Lead sponsor: Pfizer
Conditions: Healthy Volunteer
Interventions: DRUG:[14C]PF-06882961, 50 mg; DRUG:PF-06882961, 50 mg and [14C]PF-06882961, 100 ug
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: EUDRACT_NUMBER:2019-002584-10; NIH:2019

Registered primary outcomes

Total recovery of radioactivity in urine and feces, following oral administration of [14C] PF-06882961 in period 1 [Baseline through approximately hour 312 (day 14). Period 1 is 14 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.